Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.
Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB; ACTG 384 Team. Gandhi RT, et al. Among authors: hirsch ms. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34. doi: 10.1097/01.qai.0000226789.51992.3f. J Acquir Immune Defic Syndr. 2006. PMID: 16810109 Clinical Trial.
Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384.
Grady BJ, Samuels DC, Robbins GK, Selph D, Canter JA, Pollard RB, Haas DW, Shafer R, Kalams SA, Murdock DG, Ritchie MD, Hulgan T; ACTG 384 and DACS 250 Study Teams. Grady BJ, et al. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):363-70. doi: 10.1097/QAI.0b013e31822c688b. J Acquir Immune Defic Syndr. 2011. PMID: 21792066 Free PMC article. Clinical Trial.
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team. Robbins GK, et al. Among authors: hirsch ms. N Engl J Med. 2003 Dec 11;349(24):2293-303. doi: 10.1056/NEJMoa030264. N Engl J Med. 2003. PMID: 14668455 Free PMC article. Clinical Trial.
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team. Shafer RW, et al. Among authors: hirsch ms. N Engl J Med. 2003 Dec 11;349(24):2304-15. doi: 10.1056/NEJMoa030265. N Engl J Med. 2003. PMID: 14668456 Free PMC article. Clinical Trial.
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team. Smith PF, et al. Among authors: hirsch ms. Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61. doi: 10.1128/AAC.49.8.3558-3561.2005. Antimicrob Agents Chemother. 2005. PMID: 16048984 Free PMC article. Clinical Trial.
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.
Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB. Haas DW, et al. Among authors: hirsch ms. J Infect Dis. 2005 Dec 1;192(11):1931-42. doi: 10.1086/497610. Epub 2005 Nov 1. J Infect Dis. 2005. PMID: 16267764 Clinical Trial.
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.
Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW. Motsinger AA, et al. Among authors: hirsch ms. Pharmacogenet Genomics. 2006 Nov;16(11):837-45. doi: 10.1097/01.fpc.0000230413.97596.fa. Pharmacogenet Genomics. 2006. PMID: 17047492 Clinical Trial.
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M. Friedland GH, et al. J Acquir Immune Defic Syndr. 1999 Aug 1;21(4):281-92. doi: 10.1097/00126334-199908010-00005. J Acquir Immune Defic Syndr. 1999. PMID: 10428106 Clinical Trial.
496 results